BRNSBarinthus Biotherapeutics plc

BRNS Stock Price, Valuation & Chart | Barinthus Biotherapeutics plc

Compare

$0.770+0.01 (+1.29%)

At close · 02 Sept 2026, 07:59 pm

Sector: Healthcare Industry: Biotechnology BRNS intrinsic value BRNS calculated fair value vs price

Overview Financials Dividends Ratios

BRNS Historical price chart

BRNS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization31.65M

PE Ratio-0.75

EPS-1.03

Trading Volume190.46K

Today's High/Low0.79/0.74

Dividend Yield0.00

52 Week High/Low1.83/0.51

Shares Outstanding40.85M

BRNS Financial Statement

BRNS Analyst ratings

BRNS Analysis & performance metrics

BRNS Company profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome…

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential…

BRNS Management team

Name

Position

Geoffrey Lynn M.D., Ph.D.

Chief Scientific Officer

Leon Hooftman M.D.

Chief Medical Officer

William J. Enright MBACEO

Chief Executive Officer, Director & Principal Financial Officer

Gemma Brown

Principal Accounting Officer

Sarah Gilbert

Co-Founder

Adrian Hill Ph.D.

Co-Founder & Scientific Advisor

Graham GriffithsCOO

Chief Operating Officer

Name

Position

Geoffrey Lynn M.D., Ph.D.

Chief Scientific Officer

Leon Hooftman M.D.

Chief Medical Officer

William J. Enright MBACEO

Chief Executive Officer, Director & Principal Financial Officer

Gemma Brown

Principal Accounting Officer

Sarah Gilbert

Co-Founder

Adrian Hill Ph.D.

Co-Founder & Scientific Advisor

Graham GriffithsCOO

Chief Operating Officer

Management Team

Geoffrey Lynn M.D., Ph.D.

Chief Scientific Officer

Leon Hooftman M.D.

Chief Medical Officer

William J. Enright MBACEO

Chief Executive Officer, Director & Principal Financial Officer

Gemma Brown

Principal Accounting Officer

Sarah Gilbert

Co-Founder

Adrian Hill Ph.D.

Co-Founder & Scientific Advisor

Graham GriffithsCOO

Chief Operating Officer

Management

Geoffrey Lynn M.D., Ph.D.

Chief Scientific Officer

Leon Hooftman M.D.

Chief Medical Officer

William J. Enright MBACEO

Chief Executive Officer, Director & Principal Financial Officer

Gemma Brown

Principal Accounting Officer

Sarah Gilbert

Co-Founder

Adrian Hill Ph.D.

Co-Founder & Scientific Advisor

Graham GriffithsCOO

Chief Operating Officer

Total 7 executives

BRNS Frequently asked questions

What is Barinthus Biotherapeutics plc (BRNS) Stock Price?

Current stock price of Barinthus Biotherapeutics plc (BRNS) stock is $0.770. The stock price is +1.29% higher in the session. The intraday range can be seen from this page. Volume of Barinthus Biotherapeutics plc (BRNS) stock is 190.46K.

Last updated at 02 Sept 2026, 07:59 pm.

Why is the Barinthus Biotherapeutics plc (BRNS) stock price going up or down today?

The stock price of Barinthus Biotherapeutics plc (BRNS) can change with earnings, company news, and overall market sentiment. Barinthus Biotherapeutics plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Barinthus Biotherapeutics plc stock expensive at its current price?

Whether Barinthus Biotherapeutics plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BRNS on this page is -0.75. EPS on this page is -1.03. Compare those figures with peers and growth expectations before deciding if the current Barinthus Biotherapeutics plc price is justified.

How has the stock price of Barinthus Biotherapeutics plc (BRNS) performed historically?

Historical performance for Barinthus Biotherapeutics plc (BRNS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BRNS reacted to past earnings and market events.

Should I buy Barinthus Biotherapeutics plc (BRNS) stock, at this price?

Buying Barinthus Biotherapeutics plc (BRNS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.